PASTIC Dspace Repository

Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies

Show simple item record

dc.contributor.author Lateef Ahmad
dc.contributor.author Zafar Iqbal
dc.contributor.author Yasar Shah
dc.contributor.author Shabnam Nazir
dc.contributor.author Abad Khan
dc.contributor.author Khan, Muhammad Imran
dc.contributor.author Abbas Khan
dc.contributor.author Fazli Khuda
dc.contributor.author Ismail Khan
dc.date.accessioned 2023-01-20T05:17:16Z
dc.date.available 2023-01-20T05:17:16Z
dc.date.issued 2018-07-20
dc.identifier.citation Ahmad, L., Iqbal, Z., Shah, Y., Nazir, S., Khan, A., Khan, M. I., ... & Khan, I. (2018). Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies. Pakistan Journal of Pharmaceutical Sciences, 31(4). en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/16185
dc.description.abstract This study was designed to evaluate a comparative single dose (40mg) pharmacokinetics (PK) of Omeprazole (OMP) and its two metabolites, 5-hydroxy Omeprazole (5-OH-OMP) and Omeprazole sulphone (OMP-S) in poor (PM) and extensive (EM) metabolizer Pakistani healthy adult volunteers. The frequency of CYP2C19 and CYP3A4 varies widely in different populations. The present study was conducted to evaluate the PK of OMP and its two metabolites in Pakistani population and to review different studies conducted after administration of single dose of OMP. Twenty two subjects were enrolled in this study and divided into two groups. The CYP2C19 phenotyping was evaluated by the metabolic ratio of OMP to 5-OH-OMP. It was a single dose, open label study and the blood samples from subjects were collected at different time intervals until 24 hours. The PK parameters were calculated using the PK-summit software. The metabolic ratio of area under the plasma concentration-time curve AUCOMP/5-OH-OMP was 1.86 ± 0.572 and13.84 ± 2.504 for EM and PM, respectively; maximum plasma concentration (Cmax) of OMP was increased by two folds for PM while the AUC∞ was increased by 3 folds; the Cmax and AUC∞ of 5-OH-OMP decreased for PM by 2 folds while there was 3 fold increase observed in the Cmax and AUC∞ of OMP-S. The PK of OMP and its metabolites in different populations were also discussed, and issues regarding CYP2C19 and CYP3A4 genotyping were also extensively reviewed. In EM of CYP2C19 the concentration of 5-OH-OMP is higher while that of OMP-S is lower. This study as well as reported studies reveals that in PM of CYP2C19 more drugs are available for CYP3A4 to be metabolized. A correlation between CYP2C19 EM and PM activity with CYP3A4 needs to be established. en_US
dc.language.iso en en_US
dc.publisher Karachi: Pakistan Botanical Society, University of Karachi en_US
dc.subject Omeprazole en_US
dc.subject pharmacokinetics en_US
dc.subject poor and extensive metabolizer. en_US
dc.title Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account